AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
Log in

NASDAQ:ALPNAlpine Immune Sciences Stock Price, Forecast & News

$9.70
-0.48 (-4.72 %)
(As of 07/6/2020 03:32 PM ET)
Add
Compare
Today's Range
$9.68
Now: $9.70
$10.22
50-Day Range
$3.05
MA: $5.81
$12.10
52-Week Range
$2.05
Now: $9.70
$15.00
Volume2,165 shs
Average Volume2.48 million shs
Market Capitalization$180.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Read More
Alpine Immune Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.74 million
Book Value$1.59 per share

Profitability

Net Income$-41,850,000.00
Net Margins-1,236.45%

Miscellaneous

Employees48
Market Cap$180.32 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

How has Alpine Immune Sciences' stock been impacted by COVID-19 (Coronavirus)?

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALPN shares have increased by 233.3% and is now trading at $9.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alpine Immune Sciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alpine Immune Sciences.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Alpine Immune Sciences.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) released its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.17. The biotechnology company had revenue of $1.09 million for the quarter, compared to the consensus estimate of $0.38 million. Alpine Immune Sciences had a negative return on equity of 104.04% and a negative net margin of 1,236.45%. View Alpine Immune Sciences' earnings history.

What price target have analysts set for ALPN?

5 brokers have issued 1 year price objectives for Alpine Immune Sciences' stock. Their forecasts range from $8.00 to $22.00. On average, they expect Alpine Immune Sciences' share price to reach $16.00 in the next year. This suggests a possible upside of 64.9% from the stock's current price. View analysts' price targets for Alpine Immune Sciences.

Has Alpine Immune Sciences been receiving favorable news coverage?

News headlines about ALPN stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Alpine Immune Sciences.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 12,900 shares, an increase of 104.8% from the June 15th total of 6,300 shares. Based on an average daily trading volume, of 754,300 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.2% of the shares of the company are short sold. View Alpine Immune Sciences' Current Options Chain.

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the following people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 48)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $9.70.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $180.32 million and generates $1.74 million in revenue each year. The biotechnology company earns $-41,850,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is www.alpineimmunesciences.com.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.